Literature DB >> 29097342

Variable signaling activity by FOP ACVR1 mutations.

Julia Haupt1, Meiqi Xu2, Eileen M Shore3.   

Abstract

Most patients with fibrodysplasia ossificans progressiva (FOP), a rare genetic disorder of heterotopic ossification, have the same causative mutation in ACVR1, R206H. However, additional mutations within the ACVR1 BMP type I receptor have been identified in a small number of FOP cases, often in patients with disease of lesser or greater severity than occurs with R206H mutations. Genotype-phenotype correlations have been suggested in patients, resulting in classification of FOP mutations based on location within different receptor domains and structural modeling. However while each of the mutations induces increased signaling through the BMP-pSmad1/5/8 pathway, the molecular mechanisms underlying functional differences of these FOP variant receptors remained undetermined. We now demonstrate that FOP mutations within the ACVR1 receptor kinase domain are more sensitive to low levels of BMP than mutations in the ACVR1 GS domain. Our data additionally confirm responsiveness of cells with FOP ACVR1 mutations to both BMP and Activin A ligands. We also have determined that constructs with FOP ACVR1 mutations that are engineered without the ligand-binding domain retain increased BMP-pSmad1/5/8 pathway activation relative to wild-type ACVR1, supporting that the mutant receptors can function through ligand-independent mechanisms either directly through mutant ACVR1 or through indirect mechanisms.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ACVR1; BMP signaling activity; Classic/variant mutation; Fibrodysplasia ossificans progressiva; Heterotopic ossification; Protein kinase mutation

Mesh:

Substances:

Year:  2017        PMID: 29097342      PMCID: PMC5866189          DOI: 10.1016/j.bone.2017.10.027

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  47 in total

1.  Bone morphogenetic protein 2/4 in early fibromatous lesions of fibrodysplasia ossificans progressiva.

Authors:  F H Gannon; F S Kaplan; E Olmsted; G C Finkel; M A Zasloff; E Shore
Journal:  Hum Pathol       Date:  1997-03       Impact factor: 3.466

2.  Characterization of the interaction of FKBP12 with the transforming growth factor-beta type I receptor in vivo.

Authors:  T Okadome; E Oeda; M Saitoh; H Ichijo; H L Moses; K Miyazono; M Kawabata
Journal:  J Biol Chem       Date:  1996-09-06       Impact factor: 5.157

3.  Pref-1 (preadipocyte factor 1) activates the MEK/extracellular signal-regulated kinase pathway to inhibit adipocyte differentiation.

Authors:  Kyung-Ah Kim; Jung-Hyun Kim; Yuhui Wang; Hei Sook Sul
Journal:  Mol Cell Biol       Date:  2007-01-08       Impact factor: 4.272

4.  Alk2 regulates early chondrogenic fate in fibrodysplasia ossificans progressiva heterotopic endochondral ossification.

Authors:  Andria L Culbert; Salin A Chakkalakal; Edwin G Theosmy; Tracy A Brennan; Frederick S Kaplan; Eileen M Shore
Journal:  Stem Cells       Date:  2014-05       Impact factor: 6.277

Review 5.  New insights into the mechanisms of activin action and inhibition.

Authors:  Kelly L Walton; Yogeshwar Makanji; Craig A Harrison
Journal:  Mol Cell Endocrinol       Date:  2011-07-08       Impact factor: 4.102

6.  Mechanism of TGFbeta receptor inhibition by FKBP12.

Authors:  Y G Chen; F Liu; J Massague
Journal:  EMBO J       Date:  1997-07-01       Impact factor: 11.598

Review 7.  TGF-beta signalling from cell membrane to nucleus through SMAD proteins.

Authors:  C H Heldin; K Miyazono; P ten Dijke
Journal:  Nature       Date:  1997-12-04       Impact factor: 49.962

Review 8.  Targeting the TGFβ signalling pathway in disease.

Authors:  Rosemary J Akhurst; Akiko Hata
Journal:  Nat Rev Drug Discov       Date:  2012-09-24       Impact factor: 84.694

9.  ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A.

Authors:  Sarah J Hatsell; Vincent Idone; Dana M Alessi Wolken; Lily Huang; Hyon J Kim; Lili Wang; Xialing Wen; Kalyan C Nannuru; Johanna Jimenez; Liqin Xie; Nanditha Das; Genevieve Makhoul; Rostislav Chernomorsky; David D'Ambrosio; Richard A Corpina; Christopher J Schoenherr; Kieran Feeley; Paul B Yu; George D Yancopoulos; Andrew J Murphy; Aris N Economides
Journal:  Sci Transl Med       Date:  2015-09-02       Impact factor: 17.956

10.  Structure of the bone morphogenetic protein receptor ALK2 and implications for fibrodysplasia ossificans progressiva.

Authors:  Apirat Chaikuad; Ivan Alfano; Georgina Kerr; Caroline E Sanvitale; Jan H Boergermann; James T Triffitt; Frank von Delft; Stefan Knapp; Petra Knaus; Alex N Bullock
Journal:  J Biol Chem       Date:  2012-09-12       Impact factor: 5.157

View more
  14 in total

1.  Variant BMP receptor mutations causing fibrodysplasia ossificans progressiva (FOP) in humans show BMP ligand-independent receptor activation in zebrafish.

Authors:  Bettina E Mucha; Megumi Hashiguchi; Joseph Zinski; Eileen M Shore; Mary C Mullins
Journal:  Bone       Date:  2018-01-04       Impact factor: 4.398

Review 2.  The Intricate Epigenetic and Transcriptional Alterations in Pediatric High-Grade Gliomas: Targeting the Crosstalk as the Oncogenic Achilles' Heel.

Authors:  Paul Huchedé; Pierre Leblond; Marie Castets
Journal:  Biomedicines       Date:  2022-06-03

Review 3.  Fibrodysplasia ossificans progressiva (FOP): A disorder of osteochondrogenesis.

Authors:  Frederick S Kaplan; Mona Al Mukaddam; Alexandra Stanley; O Will Towler; Eileen M Shore
Journal:  Bone       Date:  2020-07-27       Impact factor: 4.398

Review 4.  The role of Activin A in fibrodysplasia ossificans progressiva: a prominent mediator.

Authors:  Hui Lin; Fuli Shi; Jiayu Gao; Ping Hua
Journal:  Biosci Rep       Date:  2019-08-02       Impact factor: 3.840

Review 5.  ACVR1 Function in Health and Disease.

Authors:  José Antonio Valer; Cristina Sánchez-de-Diego; Carolina Pimenta-Lopes; Jose Luis Rosa; Francesc Ventura
Journal:  Cells       Date:  2019-10-31       Impact factor: 6.600

Review 6.  BMP signaling and skeletal development in fibrodysplasia ossificans progressiva (FOP).

Authors:  Oscar Will Towler; Eileen M Shore
Journal:  Dev Dyn       Date:  2021-06-26       Impact factor: 2.842

7.  Fibrodysplasia ossificans progressiva mutant ACVR1 signals by multiple modalities in the developing zebrafish.

Authors:  Robyn S Allen; Benjamin Tajer; Eileen M Shore; Mary C Mullins
Journal:  Elife       Date:  2020-09-08       Impact factor: 8.140

8.  Palovarotene reduces heterotopic ossification in juvenile FOP mice but exhibits pronounced skeletal toxicity.

Authors:  John B Lees-Shepard; Sarah-Anne E Nicholas; Sean J Stoessel; Parvathi M Devarakonda; Michael J Schneider; Masakazu Yamamoto; David J Goldhamer
Journal:  Elife       Date:  2018-09-18       Impact factor: 8.140

Review 9.  Bone morphogenetic protein receptor signal transduction in human disease.

Authors:  Maria Catalina Gomez-Puerto; Prasanna Vasudevan Iyengar; Amaya García de Vinuesa; Peter Ten Dijke; Gonzalo Sanchez-Duffhues
Journal:  J Pathol       Date:  2018-11-27       Impact factor: 7.996

10.  Activins as Dual Specificity TGF-β Family Molecules: SMAD-Activation via Activin- and BMP-Type 1 Receptors.

Authors:  Oddrun Elise Olsen; Hanne Hella; Samah Elsaadi; Carsten Jacobi; Erik Martinez-Hackert; Toril Holien
Journal:  Biomolecules       Date:  2020-03-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.